A Phase II Multicenter, Two Stage Design Open Label Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy.

Trial Profile

A Phase II Multicenter, Two Stage Design Open Label Study Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs Eribulin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 May 2012 Actual patient number is 108 according to ClinicalTrials.gov.
    • 21 Apr 2012 Additional locations (Hungary, Spain, United Kingdom) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top